Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814776 | 0.86 | ACE (0.40) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL13929813 | 0.86 | APP (0.49) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL7814341 | 0.86 | ACE (0.40) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL13929781 | 0.86 | APP (0.49) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL7812043 | 0.85 | ACE (0.41) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL12797532 | 0.81 | NPY1R (0.52) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL14171435 | 0.81 | NPY1R (0.52) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL13951758 | 0.79 | APP (0.53) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL5637605 | 0.79 | FNTA (0.50) | SRCFNTAFNTBAPPNPY1R | |
| SCHEMBL5637615 | 0.79 | L3MBTL1 (0.48) | SRCFNTAFNTBAPPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | SRC 117/4885FNTA 645/4885FNTB 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.